Pay in 4 interest-free payments of $6.39 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
You should not take Wegovy tablets if: You have a personal or family history of medullary thyroid carcinoma or MEN 2 You have a history of pancreatitis You have severe kidney or liver disease You have diabetic retinopathy You have severe gastrointestinal disease including gastroparesis You are allergic to semaglutide or any ingredient in the tablet You are pregnant, planning pregnancy, or breastfeeding You are already taking other GLP-1 medicines (Wegovy injections, Ozempic, Rybelsus) You are under 18 years of age The most common side effects affect the digestive system and are usually most noticeable when starting treatment or moving to a higher dose
Originally developed by Novo Nordisk in the mid-1990s, it was characterized in pivotal research by Raun et al
: ,
Why Obesity Prevalence Alone is not an Accurate Driver for GLP-1 Sales Segmental Analysis The market is segmented by molecule class, route of administration, payer type, use-case framing, and region
Due to this effect, there has been a concern regarding the risk of intestinal obstruction with the use of GLP-1RAs
